Literature DB >> 20179635

Steroidogenesis vs. steroid uptake in the heart: do corticosteroids mediate effects via cardiac mineralocorticoid receptors?

Wenxia Chai1, Johannes Hofland, Pieter M Jansen, Ingrid M Garrelds, René de Vries, Antoon J van den Bogaerdt, Richard A Feelders, Frank H de Jong, A H Jan Danser.   

Abstract

OBJECTIVE: To test whether glucocorticoids act as the endogenous agonist of cardiac mineralocorticoid receptors, we evaluated the cardiac effects of aldosterone and corticosterone and cardiac steroidogenesis vs. steroid uptake from plasma. METHODS AND
RESULTS: Both corticosterone and aldosterone increased left ventricular pressure in the rat heart. Aldosterone decreased coronary flow, whereas corticosterone increased it. All corticosterone effects were blocked by the glucocorticoid receptor antagonist, RU486, and unaltered by the mineralocorticoid receptor antagonist, canrenoate, or the 11beta-hydroxysteroid dehydrogenase (HSD11B)2 inhibitor, carbenoxolone. Unlike mineralocorticoid receptor blockade, RU486 did not ameliorate postischemia infarct size and arrhythmias. Corticosterone, when added to the perfusion buffer, rapidly accumulated at cardiac tissue sites, reaching steady-state levels that were identical to those in coronary effluent, independently of the presence of aldosterone, RU486 or canrenoate. After stopping the perfusion, cardiac corticosterone fully washed away with a half-life of less than 1 min. Measurements of steroid-synthesizing enzyme gene expression levels in human ventricular and atrial tissue pieces from heart-beating organ donors, patients with end-stage heart failure and hypertrophic cardiomyopathy patients revealed that under no condition, the human heart was capable of synthesizing aldosterone or cortisol de novo. Yet, expression of HSD11B1, HSD11B2, mineralocorticoid receptors and glucocorticoid receptors was found, and HSD11B2 and mineralocorticoid receptors were upregulated in pathological conditions. Moreover, aldosterone reduced cardiac inotropy in a Na/K/2Cl cotransporter-dependent manner.
CONCLUSION: Both cortisol/corticosterone and aldosterone accumulate in the cardiac interstitium. The presence of HSD11B2 and mineralocorticoid receptors/glucocorticoid receptors at cardiac tissue sites allows both steroids to exert their effects via separate mechanisms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179635     DOI: 10.1097/HJH.0b013e328335c381

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  14 in total

1.  Mineralocorticoid receptors, corticosteroids and the heart: where do we stand?

Authors:  Andrea D Eckhart
Journal:  J Hypertens       Date:  2010-05       Impact factor: 4.844

Review 2.  Key developments in renin-angiotensin-aldosterone system inhibition.

Authors:  Bruno Sevá Pessôa; Nils van der Lubbe; Koen Verdonk; Anton J M Roks; Ewout J Hoorn; A H Jan Danser
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

Review 3.  Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local synthesis, regulation, and function.

Authors:  Matthew D Taves; Celso E Gomez-Sanchez; Kiran K Soma
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-05-03       Impact factor: 4.310

4.  Cardiomyocyte glucocorticoid and mineralocorticoid receptors directly and antagonistically regulate heart disease in mice.

Authors:  Robert H Oakley; Diana Cruz-Topete; Bo He; Julie F Foley; Page H Myers; Xiaojiang Xu; Celso E Gomez-Sanchez; Pierre Chambon; Monte S Willis; John A Cidlowski
Journal:  Sci Signal       Date:  2019-04-16       Impact factor: 8.192

Review 5.  Genomic and rapid effects of aldosterone: what we know and do not know thus far.

Authors:  Milla Marques Hermidorff; Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

6.  Regulation of steroidogenesis in a primary pigmented nodular adrenocortical disease-associated adenoma leading to virilization and subclinical Cushing's syndrome.

Authors:  Johannes Hofland; Wouter W de Herder; Lieke Derks; Leo J Hofland; Peter M van Koetsveld; Ronald R de Krijger; Francien H van Nederveen; Anelia Horvath; Constantine A Stratakis; Frank H de Jong; Richard A Feelders
Journal:  Eur J Endocrinol       Date:  2012-12-10       Impact factor: 6.664

Review 7.  Aldosterone and cardiovascular disease: the heart of the matter.

Authors:  B Julie He; Mark E Anderson
Journal:  Trends Endocrinol Metab       Date:  2012-10-03       Impact factor: 12.015

Review 8.  Non-genomic effect of glucocorticoids on cardiovascular system.

Authors:  Sung Ryul Lee; Hyoung Kyu Kim; Jae Boum Youm; Louise Anne Dizon; In Sung Song; Seung Hun Jeong; Dae Yun Seo; Kyoung Soo Ko; Byoung Doo Rhee; Nari Kim; Jin Han
Journal:  Pflugers Arch       Date:  2012-09-23       Impact factor: 3.657

9.  The role of renin-angiotensin-aldosterone system polymorphisms in phenotypic expression of MYBPC3-related hypertrophic cardiomyopathy.

Authors:  Iris C R M Kolder; Michelle Michels; Imke Christiaans; Folkert J Ten Cate; Danielle Majoor-Krakauer; Alexander H J Danser; Robert H Lekanne Deprez; Michael W T Tanck; Arthur A M Wilde; Connie R Bezzina; Dennis Dooijes
Journal:  Eur J Hum Genet       Date:  2012-05-09       Impact factor: 4.246

10.  Displacement of cortisol from human heart by acute administration of a mineralocorticoid receptor antagonist.

Authors:  Javaid Iqbal; Ruth Andrew; Nicholas L Cruden; Christopher J Kenyon; Katherine A Hughes; David E Newby; Patrick W F Hadoke; Brian R Walker
Journal:  J Clin Endocrinol Metab       Date:  2013-01-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.